Developer docs
API playgroundTry for free, no card

Search company profiles

Sexton Biotechnologies

Full company profile

uuid0002me5

Namestring
Sexton Biotechnologies
Legal namestring
BioLife Solutions Inc.
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Sexton Biotechnologies is a private biotechnology company founded in 2019 and headquartered in Indianapolis, Indiana. The company operates with 11-50 employees and is led by co-founders Vicky Tran and Monica Wight, both of whom are focused on business development. Sexton's corporate website is sextonbiotechnologies.com. In September 2019, Sexton closed a $5,000,000 funding round from an investor syndicate that included BioCrossroads, BioLife Solutions (NASDAQ: BLFS), Casdin Capital, and Cook Regentec; the lead investor was not disclosed in the available data.

The aggregated source material does not contain direct first-party detail on Sexton's specific product portfolio, underlying technology, customer base, pricing model, or revenue mechanics. Substantial product, technology, certification, customer, and channel data in the input explicitly describes BioLife Solutions Inc. — a publicly traded biopreservation media and cell processing company headquartered in Bothell, Washington, and a disclosed investor in Sexton. That BioLife content has not been attributed to Sexton in this analysis. As a result, Sexton's specific market positioning, product line, and operating model cannot be characterized from the available evidence, and the data gap is the dominant feature of the company profile.

Short descriptiontext

Sexton Biotechnologies is a private Indianapolis-based biotechnology company founded in 2019, with 11-50 employees and co-founders Vicky Tran and Monica Wight. In September 2019, it raised $5,000,000 from BioCrossroads, BioLife Solutions, Casdin Capital, and Cook Regentec.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIndianapolis, United States
HQ citystring
Indianapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopreservation media, cell processing solutions, cryopreservation products, human platelet lysate, cell therapy manufacturing
Industry3 codes
PRIMARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
SECONDARYHLAGAGAK
Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopreservation and Cell Processing Products
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Biopreservation Media Products
TypeOthers
Description

Sale of proprietary freeze media products (CryoStor, HypoThermosol FRS, BloodStor) and cell thawing media to biopharmaceutical, biobanking, and research customers. Products are sold in various sizes (100mL, 500mL) and configurations.

biolifesolutions.com
2Cell Performance Solutions
TypeOthers
Description

Human platelet lysate products (Stemulate-CP, nLiven PR, T-Liven PR) sold as media supplements for cell expansion in clinical and commercial manufacturing applications.

biolifesolutions.com
3Processing and Handling Equipment
TypeHardware Sales
Description

Automated aliquoting systems (Signata CT-5), cryogenic storage vials (CellSeal), and fluid management accessories for CGT manufacturing workflows.

biolifesolutions.com
4Regulatory Support Services
TypeProfessional Services
Description

Master File Letter services for IND and BLA submissions, GMP-ready ancillary materials documentation, Certificates of Analysis, and Safety Data Sheets supporting regulatory submission readiness.

biolifesolutions.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Products available in standard sizes (100 mL and 500 mL)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Volume-based sizing; GMP-ready and standard grades available; FDA Master File support included with applicable products

biolifesolutions.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sexton Biotechnologies is a private biotechnology company based in Indianapolis, founded in 2019. Per the available company and product data, it is associated with a portfolio of biopreservation media, human platelet lysate cell performance products, and automated cell processing and cryogenic storage equipment used in cell and gene therapy manufacturing workflows. Its offerings span freeze and storage media, pathogen-reduced platelet lysates, and closed-system fill/finish and cryogenic handling instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CryoStor and HypoThermosol FRS embedded in 700+ customer clinical applications
+3 more records
Product overview1 text field

BioLife Solutions offers a comprehensive portfolio of biopreservation and cell processing products organized into three main categories: (1) Cell Performance Solutions featuring human platelet lysates (Stemulate-CP, nLiven PR, T-Liven PR) that provide media supplements for reproducible cell performance over FBS and chemically defined media; (2) Processing & Handling Solutions including the Signata CT-5 automated aliquoting system, CellSeal Connect closed-system vials, and CellSeal CryoCase rigid CGT containers; and (3) Biopreservation Solutions comprising CryoStor freeze media, HypoThermosol FRS hypothermic storage media, BloodStor cryopreservation media, and Cell Thawing Media. The company's platform is embedded in over 700+ customer clinical applications, serving the regenerative medicine, biobanking, and drug discovery industries.

Product and service11 records
1Stemulate-CP Human Platelet Lysate (hPL)
CategoryCell Performance Product
Description

A xeno- and heparin-free pooled human platelet lysate used globally in clinical stem cell and immuno-oncology applications. Available in 100 mL and 500 mL sizes, manufactured from outdated FDA/AABB approved apheresis platelet units under ISO 9001:2015 Quality Management System.

2nLiven PR Human Platelet Lysate
CategoryCell Performance Product
Description

A GMP-ready pathogen-reduced human platelet lysate with E-Beam irradiation pathogen reduction meeting EU Pharmacopoeia standards and a Biodefined composition that reduces lot-to-lot variability compared to traditional PL preparations.

3T-Liven PR Human Platelet Lysate
CategoryCell Performance Product
Description

A GMP-ready human platelet lysate for closed-system bioprocessing with release against a T cell growth release assay for optimal immune cell quality. Available in bag format.

4Signata CT-5
CategoryProcessing & Handling Product
Description

A compact, benchtop aliquoting system that enables automated, aseptic filling into vials (including CellSeal Cryogenic Vials) without the need for a biosafety cabinet. Features an intuitive touchscreen interface and pre-configured fill protocols.

5CellSeal Connect
CategoryProcessing & Handling Product
Description

Closed-system transfer vials with weldable fill and retrieval and vent tubes, designed for closed-system introduction of intermediate reagents for activation, transduction, and expansion.

6CellSeal CryoCase
CategoryProcessing & Handling Product
Description

A rigid cryopreservation container designed for CGT storage, engineered as the first rigid container for closed-system fill and retrieval of larger volumes of fluid (<75 mL), with a documented reduction in particulates compared to traditional cryobags.

7CryoStor Freeze Media
CategoryBiopreservation Product
Description

Proprietary freeze media intended for cryopreservation of biologics at -196°C to -70°C, proven more effective in reducing post-preservation apoptosis and necrosis than commercial and home-brew isotonic and extracellular formulations.

8HypoThermosol FRS Freeze Media
CategoryBiopreservation Product
Description

A novel, engineered, optimized hypothermic storage and shipping media. Serum-free and protein-free, designed to provide maximum storage and shipping stability for cells and tissues at 2-8°C.

9BloodStor Freeze Media
CategoryBiopreservation Product
Description

A pure media product containing various levels of DMSO concentration from 27% to 100% DMSO, in Saline or Dextran, sterilized, tested for endotoxins, and manufactured under cGMPs with USP-grade components.

10Cell Thawing Media
CategoryBiopreservation Product
Description

Cell and tissue thawing products developed to address a Dextran shortage in the leukapheresis industry; blood products require an added buffer for long-term storage.

11Bio-T
CategoryIntra-Campus Transport Product
Description

Intra-campus transport solution for biopreservation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Publicly listed parent/strategic investor (NASDAQ: BLFS) and source of virtually all Sexton product, customer and certification data; offers an overlapping portfolio of CryoStor, HypoThermosol FRS, BloodStor, CellSeal vials, Signata CT-5 and hPL products into the same CGT and biobanking customers.

TypeBroad incumbent
Description

Global life-science tools and bioprocessing supplier (formerly GE Healthcare Life Sciences) offering cell-culture media, cryopreservation reagents and CGT workflow solutions to overlapping biopharma, CDMO and academic customers.

TypeBroad incumbent
Description

Diversified life-science incumbent with a dedicated CGT and cell-therapy services portfolio including cryopreservation media, cell-culture supplements and ancillary materials sold into the same biopharma and CDMO buyer base.

TypeBroad incumbent
Description

Global CDMO and cell-therapy media supplier offering cell-culture media, cryopreservation solutions and process-development services to CGT developers and CDMOs - overlapping with Sexton's biopreservation and hPL media offering.

5Corning Life Sciences
TypeBroad incumbent
Description

Major cell-culture media, cryogenic vials and bioprocessing consumables manufacturer serving biopharma and research customers with products that directly overlap Sexton's media and closed-system vial portfolio.

TypeDirect peer
Description

Specialist supplier of cell-isolation, cell-culture media and cryopreservation reagents for regenerative medicine and immuno-oncology research, addressing the same hPL/cryopreservation use cases as Sexton's Stemulate and CryoStor lines.

TypeBroad incumbent
Description

Industrial cell-culture media manufacturer supplying GMP-grade media and supplements for cell therapy and regenerative medicine manufacturers, competing head-on with Sexton's hPL and biopreservation media.

TypeBroad incumbent
Description

Cell-processing instruments, reagents and GMP-grade media supplier for cell and gene therapy developers, overlapping with Sexton's cell-processing, media and closed-system handling portfolio.

TypeBroad incumbent
Description

Bioprocessing equipment and consumables supplier whose cell-and-gene-therapy portfolio of single-use systems, media and process services competes for the same CDMO and therapy-developer budgets.

10Vineti
TypeEmerging player
Description

CGT-specific software and workflow provider for chain-of-custody, manufacturing orchestration and patient logistics; not a direct media peer but embedded in the same CGT commercial workflow and buyer set.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sexton Biotechnologies

Biopreservation and Cell Processing Productssextonbiotechnologies.com

Sexton Biotechnologies is a private Indianapolis-based biotechnology company founded in 2019, with 11-50 employees and co-founders Vicky Tran and Monica Wight. In September 2019, it raised $5,000,000 from BioCrossroads, BioLife Solutions, Casdin Capital, and Cook Regentec.

What Sexton Biotechnologies does

Sexton Biotechnologies is a private biotechnology company founded in 2019 and headquartered in Indianapolis, Indiana. The company operates with 11-50 employees and is led by co-founders Vicky Tran and Monica Wight, both of whom are focused on business development. Sexton's corporate website is sextonbiotechnologies.com. In September 2019, Sexton closed a $5,000,000 funding round from an investor syndicate that included BioCrossroads, BioLife Solutions (NASDAQ: BLFS), Casdin Capital, and Cook Regentec; the lead investor was not disclosed in the available data.

The aggregated source material does not contain direct first-party detail on Sexton's specific product portfolio, underlying technology, customer base, pricing model, or revenue mechanics. Substantial product, technology, certification, customer, and channel data in the input explicitly describes BioLife Solutions Inc. — a publicly traded biopreservation media and cell processing company headquartered in Bothell, Washington, and a disclosed investor in Sexton. That BioLife content has not been attributed to Sexton in this analysis. As a result, Sexton's specific market positioning, product line, and operating model cannot be characterized from the available evidence, and the data gap is the dominant feature of the company profile.

Sexton Biotechnologies firmographics

Firmographics
Name
Sexton Biotechnologies
Legal name
BioLife Solutions Inc.
Website
https://sextonbiotechnologies.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Sexton Biotechnologies is a private Indianapolis-based biotechnology company founded in 2019, with 11-50 employees and co-founders Vicky Tran and Monica Wight. In September 2019, it raised $5,000,000 from BioCrossroads, BioLife Solutions, Casdin Capital, and Cook Regentec.
Ownership category
akta.pro rank

Sexton Biotechnologies industry classification

Industry
Product category
Biopreservation and Cell Processing Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
SECONDARYHLAGAGAK
Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Biopreservation media
  • Cell processing solutions
  • Cryopreservation products
  • Human platelet lysate
  • Cell therapy manufacturing

Where Sexton Biotechnologies is headquartered

Location

Headquarters

HQ city
Indianapolis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sexton Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Biopreservation Media Products: Sale of proprietary freeze media products (CryoStor, HypoThermosol FRS, BloodStor) and cell thawing media to biopharmaceutical, biobanking, and research customers. Products are sold in various sizes (100mL, 500mL) and configurations.
  2. Cell Performance Solutions: Human platelet lysate products (Stemulate-CP, nLiven PR, T-Liven PR) sold as media supplements for cell expansion in clinical and commercial manufacturing applications.
  3. Processing and Handling Equipment: Automated aliquoting systems (Signata CT-5), cryogenic storage vials (CellSeal), and fluid management accessories for CGT manufacturing workflows.
  4. Regulatory Support Services: Master File Letter services for IND and BLA submissions, GMP-ready ancillary materials documentation, Certificates of Analysis, and Safety Data Sheets supporting regulatory submission readiness.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProducts available in standard sizes (100 mL and 500 mL)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Sexton Biotechnologies product offering

Product offering

Core offering

Sexton Biotechnologies is a private biotechnology company based in Indianapolis, founded in 2019. Per the available company and product data, it is associated with a portfolio of biopreservation media, human platelet lysate cell performance products, and automated cell processing and cryogenic storage equipment used in cell and gene therapy manufacturing workflows. Its offerings span freeze and storage media, pathogen-reduced platelet lysates, and closed-system fill/finish and cryogenic handling instruments.

Product overview

BioLife Solutions offers a comprehensive portfolio of biopreservation and cell processing products organized into three main categories: (1) Cell Performance Solutions featuring human platelet lysates (Stemulate-CP, nLiven PR, T-Liven PR) that provide media supplements for reproducible cell performance over FBS and chemically defined media; (2) Processing & Handling Solutions including the Signata CT-5 automated aliquoting system, CellSeal Connect closed-system vials, and CellSeal CryoCase rigid CGT containers; and (3) Biopreservation Solutions comprising CryoStor freeze media, HypoThermosol FRS hypothermic storage media, BloodStor cryopreservation media, and Cell Thawing Media. The company's platform is embedded in over 700+ customer clinical applications, serving the regenerative medicine, biobanking, and drug discovery industries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stemulate-CP Human Platelet Lysate (hPL) A xeno- and heparin-free pooled human platelet lysate used globally in clinical stem cell and immuno-oncology applications. Available in 100 mL and 500 mL sizes, manufactured from outdated FDA/AABB approved apheresis platelet units under ISO 9001:2015 Quality Management System.
  • nLiven PR Human Platelet Lysate A GMP-ready pathogen-reduced human platelet lysate with E-Beam irradiation pathogen reduction meeting EU Pharmacopoeia standards and a Biodefined composition that reduces lot-to-lot variability compared to traditional PL preparations.
  • T-Liven PR Human Platelet Lysate A GMP-ready human platelet lysate for closed-system bioprocessing with release against a T cell growth release assay for optimal immune cell quality. Available in bag format.
  • Signata CT-5 A compact, benchtop aliquoting system that enables automated, aseptic filling into vials (including CellSeal Cryogenic Vials) without the need for a biosafety cabinet. Features an intuitive touchscreen interface and pre-configured fill protocols.
  • CellSeal Connect Closed-system transfer vials with weldable fill and retrieval and vent tubes, designed for closed-system introduction of intermediate reagents for activation, transduction, and expansion.
  • CellSeal CryoCase A rigid cryopreservation container designed for CGT storage, engineered as the first rigid container for closed-system fill and retrieval of larger volumes of fluid (<75 mL), with a documented reduction in particulates compared to traditional cryobags.
  • CryoStor Freeze Media Proprietary freeze media intended for cryopreservation of biologics at -196°C to -70°C, proven more effective in reducing post-preservation apoptosis and necrosis than commercial and home-brew isotonic and extracellular formulations.
  • HypoThermosol FRS Freeze Media A novel, engineered, optimized hypothermic storage and shipping media. Serum-free and protein-free, designed to provide maximum storage and shipping stability for cells and tissues at 2-8°C.
  • BloodStor Freeze Media A pure media product containing various levels of DMSO concentration from 27% to 100% DMSO, in Saline or Dextran, sterilized, tested for endotoxins, and manufactured under cGMPs with USP-grade components.
  • Cell Thawing Media Cell and tissue thawing products developed to address a Dextran shortage in the leukapheresis industry; blood products require an added buffer for long-term storage.
  • Bio-T Intra-campus transport solution for biopreservation.

Quantifiable outcome

  • CryoStor and HypoThermosol FRS embedded in 700+ customer clinical applications
  • +3 more outcomes

Companies that use Sexton Biotechnologies

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Sexton Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Sexton Biotechnologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves1 record

Expansion highlights1 record

Sexton Biotechnologies competitors and assessment

Company assessment

Direct peers

  • BioLife Solutions: Publicly listed parent/strategic investor (NASDAQ: BLFS) and source of virtually all Sexton product, customer and certification data; offers an overlapping portfolio of CryoStor, HypoThermosol FRS, BloodStor, CellSeal vials, Signata CT-5 and hPL products into the same CGT and biobanking customers.
  • STEMCELL Technologies: Specialist supplier of cell-isolation, cell-culture media and cryopreservation reagents for regenerative medicine and immuno-oncology research, addressing the same hPL/cryopreservation use cases as Sexton's Stemulate and CryoStor lines.

Broad incumbents

  • Cytiva: Global life-science tools and bioprocessing supplier (formerly GE Healthcare Life Sciences) offering cell-culture media, cryopreservation reagents and CGT workflow solutions to overlapping biopharma, CDMO and academic customers.
  • Thermo Fisher Scientific: Diversified life-science incumbent with a dedicated CGT and cell-therapy services portfolio including cryopreservation media, cell-culture supplements and ancillary materials sold into the same biopharma and CDMO buyer base.
  • Lonza Group: Global CDMO and cell-therapy media supplier offering cell-culture media, cryopreservation solutions and process-development services to CGT developers and CDMOs - overlapping with Sexton's biopreservation and hPL media offering.
  • Corning Life Sciences: Major cell-culture media, cryogenic vials and bioprocessing consumables manufacturer serving biopharma and research customers with products that directly overlap Sexton's media and closed-system vial portfolio.
  • FUJIFILM Irvine Scientific: Industrial cell-culture media manufacturer supplying GMP-grade media and supplements for cell therapy and regenerative medicine manufacturers, competing head-on with Sexton's hPL and biopreservation media.
  • Miltenyi Biotec: Cell-processing instruments, reagents and GMP-grade media supplier for cell and gene therapy developers, overlapping with Sexton's cell-processing, media and closed-system handling portfolio.
  • Sartorius: Bioprocessing equipment and consumables supplier whose cell-and-gene-therapy portfolio of single-use systems, media and process services competes for the same CDMO and therapy-developer budgets.

Emerging players

  • Vineti: CGT-specific software and workflow provider for chain-of-custody, manufacturing orchestration and patient logistics; not a direct media peer but embedded in the same CGT commercial workflow and buyer set.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sexton Biotechnologies social profiles

Digital presence

Sexton Biotechnologies compliance and trust

Trust signal

Compliance4 records

Sexton Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sexton Biotechnologies leadership team

Management profile

Number of profiles

Profiles2 records

Sexton Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sexton Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sexton Biotechnologies

What does Sexton Biotechnologies do?

Sexton Biotechnologies is a private biotechnology company based in Indianapolis, founded in 2019. Per the available company and product data, it is associated with a portfolio of biopreservation media, human platelet lysate cell performance products, and automated cell processing and cryogenic storage equipment used in cell and gene therapy manufacturing workflows. Its offerings span freeze and storage media, pathogen-reduced platelet lysates, and closed-system fill/finish and cryogenic handling instruments.

Is Sexton Biotechnologies a public or private company?

Sexton Biotechnologies is a public company. It is classified as venture growth investor backed and is currently operating.

When was Sexton Biotechnologies founded?

Sexton Biotechnologies was founded in 2019. It employs 51 to 100 people.

Where is Sexton Biotechnologies based?

Sexton Biotechnologies is headquartered in Indianapolis, United States, in the North America region.

How does Sexton Biotechnologies make money?

Four revenue lines are on record. Biopreservation Media Products are the primary driver. The others are cell Performance Solutions, processing and Handling Equipment and regulatory Support Services.

Who are Sexton Biotechnologies's main competitors?

Direct peers on record are BioLife Solutions and STEMCELL Technologies. Broad incumbents are Cytiva, Thermo Fisher Scientific, Lonza Group, Corning Life Sciences, FUJIFILM Irvine Scientific, Miltenyi Biotec and Sartorius. Vineti is listed as an emerging player.

Does Sexton Biotechnologies have an API?

No public API is recorded for Sexton Biotechnologies.

What industry is Sexton Biotechnologies in?

Sexton Biotechnologies's product category is Biopreservation and Cell Processing Products. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats), with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBioLife Solutions Files Form S-3 Registration Statement to Register Shares from Completed AcquisitionsBioLife Solutions has filed a registration statement on Form S-3 with the SEC to register approximately 10.7 million shares of restricted common stock held by stockholders of its previously acquired companies Global Cooling/Stirling Ultracold, SciSafe Holdings, and Sexton Biotechnologies, as well as shares held by Casdin Capital. The company is not issuing new shares but is fulfilling registration obligations associated with its 2019, 2020, and 2021 acquisitions. CEO Mike Rice stated that the registration reflects the company's strategy of expanding through acquisitions in the cell and gene therapy bioproduction market.PR NewswireBioLife Solutions Closes Acquisition of Sexton BiotechnologiesBioLife Solutions, Inc. has completed the acquisition of Sexton Biotechnologies, a company specializing in bioproduction tools for cell and gene therapy. The acquisition brings Sexton's portfolio of products, which are instrumental in over 50 clinical trials, into BioLife's offerings, enhancing its capabilities in the biopharmaceutical market. BioLife aims to leverage this acquisition to boost revenue and improve clinical outcomes in the cell and gene therapy space.BioSpaceSexton Biotechnologies to be Acquired by Biolife SolutionsBioLife Solutions agreed to acquire Sexton Biotechnologies for $30 million in a deal announced Aug. 9, 2021. Sexton, a cell and gene therapy manufacturing tool provider, will become BioLife's Chief Technology Officer. The acquisition aims to expand BioLife's portfolio with Sexton's cryogenic storage and fluid handling products.BioSpaceBioLife Solutions to Acquire Sexton Biotechnologies to Expand Cell and Gene Therapy Tools PortfolioBioLife Solutions has entered into a definitive agreement to acquire the remaining outstanding shares of Sexton Biotechnologies for $24.0 million in stock, with the transaction expected to close by September 1, 2021. The acquisition adds proprietary cell therapy packaging, media, and automation tools to BioLife's portfolio, which are currently used in over 50 clinical trials. Management anticipates the deal will be moderately accretive to adjusted net income per share starting in 2022.PR NewswireBioLife Solutions to Acquire Sexton Biotechnologies to Expand Cell and Gene Therapy Tools PortfolioBioLife Solutions, Inc. announced its acquisition of Sexton Biotechnologies, Inc. for $24 million in newly issued shares, expected to close by September 1, 2021. The deal aims to enhance BioLife's portfolio in cell and gene therapy, leveraging Sexton's proprietary bioproduction tools already used in over 50 clinical trials. This acquisition is anticipated to contribute approximately $2 million to BioLife's 2021 revenue, with further growth expected in subsequent years.PR NewswireSexton Biotechnologies Partners with BioSpherix to Create a Fully-Enclosed, Modular Fill-Finish System with Rapid Deployment for Emerging Cell and Gene Therapy NeedsSexton Biotechnologies announced a new collaboration with BioSpherix Medical to combine their technologies for cell and gene therapy fill-finish manufacturing. The partnership integrates Sexton's AF-500 automated fill system with BioSpherix's Cytocentric® isolator technology to create a fully enclosed, modular GMP-compliant solution that can be rapidly deployed and installed within a biosafety cabinet. The companies aim to address the bottlenecks and costs associated with traditional cleanroom facilities, particularly as the COVID-19 pandemic has accelerated therapeutic development while tightening supply chains.PR NewswireSexton Biotechnologies Releases Flexible Automation Filling System - Signata CT-5Sexton Biotechnologies has announced the release of its Signata CT-5, a cell and gene therapy processing system designed to integrate traditionally manual processes into an automated workflow for biotech manufacturing. The system allows users to incorporate automation earlier in development and provides flexibility to fill into both cryobags and cryogenic vials. The company began rolling out the new system to initial customers following its official release at ISTC Virtual.PR NewswireSexton Biotechnologies and Ikeda Scientific Provide Human Platelet Lysate to Japanese Regenerative Medicine Product ManufacturersSexton Biotechnologies and Ikeda Scientific announced the completion of the certification process for Sexton's pathogen-reduced human platelet lysate (nLiven PR) with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This approval allows the product to be used as a raw material for manufacturing regenerative medicine products in Japan. The certification addresses global regulatory expectations by utilizing a validated E-beam process for viral inactivation.PR NewswireGrowth Supplement Boosts CAR-T Cell Performance - Sexton Biotechnologies Releases T-Cell Specific Human Platelet LysateSexton Biotechnologies announced the launch of T-Liven-PR, a T-Cell validated Human Platelet Lysate (hPL) product designed to enhance CAR-T cell manufacturing performance. In a published study conducted with Baylor College of Medicine, CAR-T cells expanded using T-Liven-PR demonstrated enhanced proliferation, prolonged in vivo persistence, and potent anti-tumour responses in both haematological and solid tumour mouse models with significantly improved survival rates. The product, manufactured from expired transfusable platelet units using E-beam pathogen reduction technology, is now commercially available as an off-the-shelf 100ml bag with customisation options for CAR-T therapy manufacturers.FinSMEsSexton Biotechnologies Raises $5M in FundingSexton Biotechnologies raised $5M in growth funding from BioLife Solutions, Casdin Capital, BioCrossroads, and Cook Regentec. The Indianapolis-based biotech will use the funds to expand research and product development and scale commercialization of its cell and gene therapy tools. The company plans to lease space at Cook Regentec's facility through 2024.